TRIAL DATA
Dual immunotherapy shows durable benefit in MSI-H colorectal cancer — Journal of Clinical Oncology
Long-term follow-up from the CheckMate 8HW phase 3 trial examined outcomes in patients with MSI-H/dMMR (microsatellite instability-high/mismatch repair-deficient) metastatic colorectal cancer treated with nivolumab plus ipilimumab versus nivolumab alone. The study included subgroup analyses of treatment-free status and outcomes in long-term survivors, providing insights into which patients may achieve durable disease control with combination immunotherapy.
What this means
If your tumor is MSI-H or dMMR, this study adds to evidence that immunotherapy can provide long-lasting control. Some patients may even reach a point where they can stop treatment while maintaining benefit—discuss with your oncologist whether this applies to you.